Inhibitor Therapeutics, Inc. (INTI) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
INTI representa a Inhibitor Therapeutics, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0).
Ultimo analisis: 18 mar 2026Inhibitor Therapeutics, Inc. (INTI) Resumen de Asistencia Médica y Tuberías
Inhibitor Therapeutics, Inc., operating in the biotechnology sector, focuses on developing and commercializing therapeutics for cancer and non-cancerous proliferation disorders. Their primary focus is on SUBA-Itraconazole, an oral formulation of itraconazole, targeting prostate and lung cancer, with a completed Phase 2b study for basal cell carcinoma nevus syndrome.
Tesis de Inversión
Inhibitor Therapeutics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on SUBA-Itraconazole for prostate and lung cancer, along with positive Phase 2b data for basal cell carcinoma nevus syndrome, offers potential upside. However, the company's small market capitalization of $0.02 billion and negative P/E ratio of -4.43 indicate significant financial challenges. The company's success hinges on the successful completion of clinical trials and subsequent commercialization of SUBA-Itraconazole. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. The negative beta of -0.36 suggests a potential lack of correlation with the broader market, which could offer diversification benefits. However, the OTC listing introduces liquidity and regulatory risks.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.02 billion indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -4.43 reflects the company's current lack of profitability and reliance on future drug development success.
- Beta of -0.36 suggests a potential lack of correlation with the broader market, which could offer diversification benefits.
- Focus on SUBA-Itraconazole, an oral formulation of itraconazole, targeting prostate and lung cancer, offering a potentially novel treatment option.
- Positive Phase 2b study completed for SUBA-Itraconazole in the treatment of basal cell carcinoma nevus syndrome, demonstrating potential efficacy.
Competidores y Pares
Fortalezas
- Proprietary SUBA-Itraconazole formulation.
- Positive Phase 2b clinical trial data for basal cell carcinoma nevus syndrome.
- Experienced management team.
- Focus on unmet medical needs in oncology.
Debilidades
- Limited financial resources.
- Small market capitalization.
- Dependence on the success of SUBA-Itraconazole.
- OTC listing introduces liquidity and regulatory risks.
Catalizadores
- Upcoming: Announcement of results from ongoing clinical trials of SUBA-Itraconazole for prostate and lung cancer.
- Upcoming: Potential strategic partnerships for clinical development and commercialization.
- Upcoming: Regulatory submissions for SUBA-Itraconazole in various cancer indications.
- Ongoing: Continued development of novel drug delivery systems for itraconazole.
- Ongoing: Exploration of geographic expansion into international markets.
Riesgos
- Potential: Failure to obtain regulatory approvals for SUBA-Itraconazole.
- Potential: Unfavorable clinical trial results.
- Potential: Competition from larger pharmaceutical companies.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on the success of SUBA-Itraconazole.
Oportunidades de crecimiento
- Expansion of SUBA-Itraconazole into additional cancer indications: Inhibitor Therapeutics can explore the potential of SUBA-Itraconazole in treating other types of cancer beyond prostate and lung cancer. The market for cancer therapeutics is projected to reach $200 billion by 2028, offering significant revenue potential. This expansion would require further clinical trials and regulatory approvals, potentially taking 3-5 years.
- Strategic partnerships for clinical development and commercialization: Collaborating with larger pharmaceutical companies can provide Inhibitor Therapeutics with access to funding, expertise, and infrastructure needed to advance SUBA-Itraconazole through clinical trials and commercialization. The timeline for securing such partnerships can vary, but typically takes 1-2 years. Successful partnerships can significantly accelerate the development and commercialization process.
- Out-licensing or sale of SUBA-Itraconazole: Inhibitor Therapeutics could out-license or sell the rights to SUBA-Itraconazole to a larger pharmaceutical company, generating upfront revenue and potential milestone payments. The market for licensing deals in the pharmaceutical industry is active, with deal values ranging from millions to billions of dollars. This strategy could provide a quicker return on investment compared to pursuing independent commercialization.
- Development of novel drug delivery systems for itraconazole: Exploring new drug delivery systems for itraconazole could improve its efficacy and reduce side effects, enhancing its market potential. The market for drug delivery technologies is growing, driven by the demand for more effective and patient-friendly drug formulations. This development could take 2-4 years and require significant research and development investment.
- Geographic expansion into international markets: Expanding into international markets, such as Europe and Asia, can significantly increase the potential market for SUBA-Itraconazole. The global market for cancer therapeutics is substantial, with significant growth opportunities in emerging markets. This expansion would require regulatory approvals in each target market, potentially taking 3-5 years.
Oportunidades
- Expansion of SUBA-Itraconazole into additional cancer indications.
- Strategic partnerships for clinical development and commercialization.
- Out-licensing or sale of SUBA-Itraconazole.
- Development of novel drug delivery systems for itraconazole.
Amenazas
- Competition from larger pharmaceutical companies.
- Failure to obtain regulatory approvals.
- Unfavorable clinical trial results.
- Patent expiration.
Ventajas competitivas
- Proprietary SUBA-Itraconazole formulation.
- Patent protection for its therapies.
- Positive Phase 2b clinical trial data for basal cell carcinoma nevus syndrome.
- Expertise in developing and commercializing cancer therapeutics.
Acerca de INTI
Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Originally named HedgePath Pharmaceuticals, Inc., the company rebranded in August 2019 to Inhibitor Therapeutics, Inc. The company is dedicated to the development and commercialization of novel therapeutics aimed at treating patients suffering from various cancers and non-cancerous proliferation disorders. Their primary focus is on the development of therapies for prostate and lung cancer, utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole. The company has completed a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome, indicating potential efficacy in this area. Inhibitor Therapeutics operates within the biotechnology industry, concentrating on pharmaceutical development within the United States. The company's strategy revolves around identifying and developing targeted therapies that can address unmet medical needs in oncology and related fields. With a small team of 3 employees, Inhibitor Therapeutics is focused on advancing its pipeline and seeking strategic partnerships to support its clinical and commercialization efforts.
Qué hacen
- Develops therapeutics for cancer and non-cancerous proliferation disorders.
- Focuses on therapies for prostate and lung cancer.
- Utilizes SUBA-Itraconazole, an oral formulation of itraconazole.
- Conducts clinical trials to evaluate the efficacy of its therapies.
- Seeks regulatory approvals for its therapies.
- Aims to commercialize its therapies in the United States.
Modelo de Negocio
- Develops and patents novel therapeutic compounds.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved therapies through partnerships or direct sales.
Contexto de la Industria
Inhibitor Therapeutics, Inc. operates in the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Competitors include companies developing similar therapies for prostate and lung cancer. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.
Clientes Clave
- Patients with cancer and non-cancerous proliferation disorders.
- Healthcare providers who treat these patients.
- Pharmaceutical companies that may partner with or acquire Inhibitor Therapeutics.
Finanzas
Gráfico e información
Precio de la acción de Inhibitor Therapeutics, Inc. (INTI): Price data unavailable
Últimas noticias
-
NXT Stock: No. 1 Solar Play, IBD Stock Of The Day, Breaks Out On War, Outlook
Investor's Business Daily · 24 mar 2026
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para INTI.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para INTI.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de INTI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Francis E. O'Donnell Jr.
CEO
Francis E. O'Donnell Jr. serves as the CEO of Inhibitor Therapeutics, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in companies focused on drug development and commercialization. His expertise spans areas such as clinical trials, regulatory affairs, and business development. He is responsible for overseeing the strategic direction and operations of Inhibitor Therapeutics.
Historial: Under Mr. O'Donnell's leadership, Inhibitor Therapeutics has focused on advancing the development of SUBA-Itraconazole for cancer treatment. A key milestone has been the completion of a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. He is managing a team of 3 employees.
Información del mercado OTC de INTI
The OTC Other tier represents the lowest tier of the OTC market, indicating that Inhibitor Therapeutics, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited liquidity, price volatility, and information asymmetry.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity due to OTC listing.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Information asymmetry.
- Higher risk of delisting.
- Verify the company's financial statements.
- Assess the company's management team and track record.
- Review the company's SEC filings (if any).
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Positive Phase 2b clinical trial data for SUBA-Itraconazole.
- Focus on developing therapies for unmet medical needs in oncology.
- Experienced management team.
- Patent protection for its therapies.
Preguntas Comunes Sobre INTI
¿Cuáles son los factores clave para evaluar INTI?
Evaluar INTI implica revisar los fundamentales, el consenso de analistas y los factores de riesgo. Fortaleza clave: Proprietary SUBA-Itraconazole formulation.. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for SUBA-Itraconazole.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de INTI?
El MoonshotScore califica a INTI de 0 a 100 en salud financiera, impulso del mercado y factores de riesgo. Puntuaciones superiores a 70 indican calificaciones más altas, 50-70 moderadas y por debajo de 50 calificaciones más bajas. Se recalcula diariamente. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de INTI?
Los precios de INTI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre INTI?
La cobertura de analistas para INTI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en INTI?
Las categorías de riesgo para INTI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for SUBA-Itraconazole.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de INTI?
La relación P/E para INTI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está INTI sobrevalorada o infravalorada?
Determinar si Inhibitor Therapeutics, Inc. (INTI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de INTI?
Inhibitor Therapeutics, Inc. (INTI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.
- AI analysis pending for INTI.